Publications by Yuqing Xie | EPFL Graph Search

Related publications (8)

Engineering T Cell Trafficking and Function for Enhanced Cancer Immunotherapy

In the past decades, breakthroughs in cancer immunotherapy have led to unprecedented clinical responses in patients with advanced-stage cancers that would otherwise be fatal. However, treatment of many solid organ malignancies with highly immunosuppressive ...

EPFL2022

IL-10-expressing CAR T cells resist dysfunction and mediate durable clearance of solid tumors and metastases

Li Tang, Yi Wang, Yugang Guo, Bing Feng, Yang Zhao, Yuqing Xie, Xiaomeng Hu, Min Gao

The success of chimeric antigen receptor (CAR) T cell therapy in treating several hematopoietic malignancies has been difficult to replicate in solid tumors, in part because of T cell exhaustion and eventually dysfunction. To counter T cell dysfunction in ...

Nature Portfolio2024

Aberrant hyperexpression of the RNA binding protein FMRP in tumors mediates immune evasion

Douglas Hanahan, Nadine Fournier, Mélanie Louise Tichet, Krisztian Homicsko, Agnieszka Alicja Chryplewicz, Mohammad Sadegh Saghafinia, Yuqing Xie, Dalya Ataca, Qiqun Zeng, Jeremy Gilles Louis Guillot, Simge Yücel

Many human cancers manifest the capability to circumvent attack by the adaptive immune system. In this work, we identified a component of immune evasion that involves frequent up-regulation of fragile X mental retardation protein (FMRP) in solid tumors. FM ...

American Association for the Advancement of Science2022

Cancer-cell stiffening via cholesterol depletion enhances adoptive T-cell immunotherapy

Georg Fantner, Li Tang, Mahmut Selman Sakar, Yugang Guo, Murat Kaynak, Mélanie Thérèse Marie Hannebelle, Armand Kurum, Kewen Lei, Lucia Bonati, Yuqing Xie, Min Gao, Veronika Cencen

Cancer cells enriched in cholesterol in their plasma membrane impair T-cell-mediated cytotoxicity, which can be augmented by stiffening the cancer cells via cholesterol depletion, as shown in mouse models of adoptive T-cell immunotherapy. Malignant transfo ...

2021

Immunoengineering with biomaterials for enhanced cancer immunotherapy

Li Tang, Lixia Wei, Yuqing Xie

Cancer immunotherapy has recently shown dramatic clinical success inducing durable response in patients of a wide variety of malignancies. Further improvement of the clinical outcome with immune related cancer treatment requests more exquisite manipulation ...

2018

Redox-responsive interleukin-2 nanogel specifically and safely promotes the proliferation and memory precursor differentiation of tumor-reactive T-cells

Li Tang, Lixia Wei, Yuqing Xie

Interleukin-2 (IL-2) is a potent T-cell mitogen that can adjuvant anti-cancer adoptive T-cell transfer (ACT) immunotherapy by promoting T-cell engraftment. However, the clinical applications of IL-2 in combination with ACT are greatly hindered by the sever ...

2019

A Manganese Phosphate Nanocluster Activates the cGAS‐STING Pathway for Enhanced Cancer Immunotherapy

Li Tang, Yugang Guo, Armand Kurum, Kewen Lei, Yuqing Xie, Min Gao, Yu Zhao, Xiaomeng Hu

Targeting the stimulator of interferon genes (STING) pathway with cyclic dinucleotides (CDNs), the natural STING agonists, is a promising immunotherapeutic strategy for cancer. However, the clinical application of natural CDNs as therapeutics is greatly hi ...

2021

Il10/fc fusion proteins useful as enhancers of immunotherapies

Li Tang, Yugang Guo, Yuqing Xie

The present disclosure relates to new agents useful for anti-cancer therapy such as anti-cancer adoptive T-cell transfer (ACT) immunotherapy or immune check-point blockade therapy and related compositions, uses and methods thereof. ...

2021